Search Results - "Slusarchyk, D.A."

Arylpropanolamines : Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations by WASHBURN, W. N, HARPER, T. W, DEJNEKA, T, AHMED, S, CARINGAL, Y, HANGELAND, J, ZHANG, M, CHENG, P. T. W, RUSSELL, A. D, SKWISH, S, SLUSARCHYK, D. A, ALLEN, G. T, WU, G, FROHLICH, B. H, ABBOA-OFFEI, B. E, CAP, M, WALDRON, T. L, GEORGE, R. J, TESFAMARIAM, B, DICKINSON, K. E, SEYMOUR, A. A, SHER, P. M, GODFREY, J. D, MCCANN, P, GIROTRA, R, SHAO, C, ZHANG, H, GAVAI, A, MIKKILINENI, A

Get full text

Arylpropanolamines: Selective β 3 agonists arising from strategies to mitigate phase I metabolic transformations by Washburn, W.N., Harper, T.W., Wu, G., Godfrey, J.D., McCann, P., Girotra, R., Shao, C., Zhang, H., Gavai, A., Mikkilineni, A., Dejneka, T., Ahmed, S., Caringal, Y., Hangeland, J., Zhang, M., Cheng, P.T.W., Russell, A.D., Skwish, S., Slusarchyk, D.A., Allen, G.T., Frohlich, B.H., Abboa-Offei, B.E., Cap, M., Waldron, T.L., George, R.J., Tesfamariam, B., Dickinson, K.E., Seymour, A.A., Sher, P.M.

“…Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective β 3 agonists is complicated by their propensity to undergo metabolic…”
Get full text

BMS-201620: a selective beta 3 agonist by Washburn, W.N., Sun, C.-Q., Bisacchi, G., Wu, G., Cheng, P.T., Sher, P.M., Ryono, D., Gavai, A.V., Poss, K., Girotra, R.N., McCann, P.J., Mikkilineni, A.B., Dejneka, T.C., Wang, T.C., Merchant, Z., Morella, M., Arbeeny, C.M., Harper, T.W., Slusarchyk, D.A., Skwish, S., Russell, A.D., Allen, G.T., Tesfamariam, B., Frohlich, B.H., Abboa-Offei, B.E., Cap, M., Waldron, T.L., George, R.J., Young, D., Dickinson, K.E., Seymour, A.A.

“…Graphic A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human β 3 adrenergic receptor agonist…”
Get full text

BMS-196085 : A potent and selective full agonist of the human β3 adrenergic receptor by GAVAI, A. V, SHER, P. M, WANG, T. C, SUN, C. Q, SLUSARCHYK, D. A, SKWISH, S, ALLEN, G. T, HILLYER, D. E, FROHLICH, B. H, ABBOA-OFFEI, B. E, CAP, M, WALDRON, T. L, MIKKILINENI, A. B, GEORGE, R. J, TESFAMARIAM, B, HARPER, T. W, CIOSEK, C. P, YOUNG, D. A, DICKINSON, K. E, SEYMOUR, A. A, ARBEENY, C. M, WASHBURN, W. N, POSS, K. M, MCCANN, P. J, GIROTRA, R. N, FISHER, L. G, WU, G, BEDNARZ, M. S, MATHUR, A

Get full text

BMS-196085: A potent and selective full agonist of the human β 3 adrenergic receptor by Gavai, A.V., Sher, P.M., Mikkilineni, A.B., Poss, K.M., McCann, P.J., Girotra, R.N., Fisher, L.G., Wu, G., Bednarz, M.S., Mathur, A., Wang, T.C., Sun, C.Q., Slusarchyk, D.A., Skwish, S., Allen, G.T., Hillyer, D.E., Frohlich, B.H., Abboa-Offei, B.E., Cap, M., Waldron, T.L., George, R.J., Tesfamariam, B., Harper, T.W., Ciosek, C.P., Young, D.A., Dickinson, K.E., Seymour, A.A., Arbeeny, C.M., Washburn, W.N.

“…A series of 4-hydroxy-3-methylsulfonanilido-1,2-diarylethylamines were prepared and evaluated for their human β 3 adrenergic receptor agonist activity. SAR…”
Get full text